Afya (1AY) AI Stock Analysis

1 Followers

Afya

(Frankfurt:1AY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong profitability and cash conversionHigh operating margins and strong cash conversion indicate that Afya’s earnings are supported by underlying business cash generation. This provides capacity to fund medical education growth, sustain investment, and maintain financial resilience across the next several quarters.

Negative Factors

Investment cycle is pressuring marginsHigher product, marketing and team spending is reducing near-term profitability while Afya invests for future growth. The business must convert these expenditures into durable revenue gains; otherwise, structurally higher costs could limit margin sustainability.

Afya (1AY) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 960.25M
Dividend Yield: 6.28%
Average Volume (3M): 344
Price to Earnings (P/E): 6.4
Beta (1Y): -0.02
Revenue Growth: 9.07%
EPS Growth: 14.88%
Country: Germany
Employees: 9,395
Sector: Consumer Defensive
Sector Strength: 62
Industry: Education & Training Services

Afya Business Overview & Revenue Model

Company Description

Afya Limited, operating through its subsidiaries, is a prominent medical education provider in Brazil. The company delivers a comprehensive array of educational products and services primarily focused on the medical field, encompassing medical school...

Afya Earnings Call Summary

Earnings Call Date:Aug 12, 2026(Q2-2026)|% Change Since:-21.24%|Next Earnings Date:Nov 11, 2026

Earnings Call SentimentPositive

The call presented a predominately positive operational and financial picture: revenue, net income, EPS, cash flow and several unit-growth metrics (medical seats, students, clinical management payers) all improved year-over-year. However, near-term margin pressure driven by an investment cycle, a mix-driven slowdown in continued education revenue despite strong student growth, engagement softness in some product lines (Whitebook monthly users) and a relatively high cost of debt introduce tangible execution and timing risks. On balance the company shows resilient cash generation, conservative leverage and active capital returns while investing for future growth.

Positive Updates

Revenue Growth

Revenue for the first half of 2026 reached BRL 1.985 billion, up 7% year-over-year; second-quarter revenue was BRL 972 million, up 6% year-over-year.

Negative Updates

Margin Contraction Due to Investment Cycle

Adjusted EBITDA margin contracted ~190 basis points YoY to 46.2% for the six-month period (Q2 margin 41.8%), primarily reflecting lower gross profit contribution from continued education and higher sales & marketing and product investment across continued education and medical practice solutions.

Company Guidance

Management maintained full‑year adjusted EBITDA guidance of BRL 1.7–1.8 billion (H1 adjusted EBITDA BRL 918m; Q2 BRL 470m), with H1 revenue BRL 1.985 billion (up 7% YoY) and Q2 revenue BRL 972m (up 6%); CapEx guidance remains BRL 340–380m (H1 spent ~30% of guidance, with acceleration expected in H2); they expect an effective tax rate around 10% for 2026 after a ~BRL 20m Pillar Two benefit. Balance‑sheet and cash metrics supporting the guidance include net debt BRL 1,394m (net debt/EBITDA ex‑IFRS16 0.8x), gross debt BRL 2.4bn with average cost 15.1% and duration 3.7 years, operating cash flow BRL 806m (up 3% YoY) and H1 free cash flow to equity BRL 423m; capital returned to shareholders totaled BRL 448m in H1 (106% of FCFE), including BRL 307m in Q2 dividends (40% of 2025 net income) and 2.6m shares repurchased of a 4m program (1.4m remaining). Management reiterated targeted outcomes for continuing education (high single‑digit growth in H2), a disciplined M&A threshold (minimum ~20% unlevered IRR), and the aim to maintain conservative leverage while executing product and investment initiatives.

Afya Risk Analysis

Afya disclosed 69 risk factors in its most recent earnings report. Afya reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.We may require additional funds to continue our expansion strategy. If we are unable to obtain adequate financing on favorable terms to complete any potential acquisition and implement our expansion plans, our growth strategy may be materially and adversely affected.Q4, 2020

Afya Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:1AY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LOPE	74Outperform	$3.93B	13.01	36.47%	―	5.30%	26.08%
PRDO	72Outperform	$1.88B	9.15	17.70%	2.34%	11.68%	18.98%
LAUR	71Outperform	$4.77B	12.19	34.23%	―	20.90%	99.99%
PXED	70Outperform	$794.42M	8.71	28.66%	2.93%	0.97%	-34.18%
STRA	69Neutral	$1.65B	201.62	0.60%	4.10%	2.79%	-94.16%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

* Consumer Defensive Sector Average

Performance Comparison

DE:1AY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1AY	Afya Limited Class A	8.90	-2.67	-23.08%
PRDO	Perdoceo Education Corporation	26.55	-2.99	-10.13%
LOPE	Grand Canyon Education	122.25	-43.85	-26.40%
STRA	Strategic Education	58.47	-15.30	-20.74%
LAUR	Laureate Education	33.29	2.90	9.54%
PXED	Phoenix Education Partners, Inc.	21.51	-10.09	-31.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Afya AI Stock Analysis